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Background: The distinction between lobular neoplasia of the breast and ductal carcinoma in situ has important
therapeutic implications. In some cases, it is very difficult to determine whether the morphology of the lesion is
ductal or lobular. The aim of this study was to evaluate the value of E-cadherin and β-catenin expression through
the immunophenotypical characterization of carcinoma in situ with mixed pattern (CISM).
Methods: A total of 25 cases of CISM were analyzed considering cytology/mixed architecture (ductal and lobular),
nuclear pleomorphism, loss of cell cohesion, and presence of comedonecrosis. The immunophenotype pattern was
considered E-cadherin positive and β-catenin positive, or negative.
Results: Nineteen (76%) cases presented a mixed cytology and / or architectural pattern, two (8%) presented nuclear
pleomorphism, two (8%) presented mixed cytology and nuclear pleomorphism, and two (8%) presented
comedonecrosis and nuclear pleomorphism. A complete positivity for E-cadherin and β-catenin was observed in 11
cases (44%). In one case, the lesion was negative for both markers and showed nuclear pleomorphis. Thirteen lesions
showed negative staining in areas of lobular cytology and positive staining in cells presenting the ductal pattern.
Conclusions: The expression of E-cadherin and β-catenin, combined with cytological and architectural analysis, may
highlight different immunophenotypes and improve classification of CISM.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
1693384202970681
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Introdução: A distinção entre neoplasia lobular e carcinoma ductal in situ tem importantes implicações
terapêuticas. No entanto, em alguns casos, é muito difícil determinar se a morfologia da lesão é ductal ou lobular.
O objetivo deste estudo foi avaliar a expressão de E-caderina e β-catenina na caracterização imunofenotípica dos
carcinomas in situ de padrão misto (CISM).
Métodos: Um total de vinte e cinco casos de CISM foram analisados considerando a citologia/arquitetura mista
(ductal e lobular), pleomorfismo nuclear e presença de comedonecrose. A expressão imuno-histoquímica foi
considerada positiva para E-caderina e β-catenina, ou negativa.
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Resultados: Dezenove (76%) casos apresentavam somente citologia e/ou padrão arquitetural misto (ductal
e lobular), dois casos (8%) apresentaram somente pleomorfismo nuclear, dois casos (8%) apresentavam citologia
mista e pleomorfismo nuclear, e dois casos (8%) tinham comedonecrose e pleomorfismo nuclear. Uma positividade
completa para E-caderina e β-catenina foi observada em 11 casos (44%). Em um caso a lesão foi negativa para
ambos marcadores e apresentava pleomorfismo nuclear e comedonecrose. Em 13 lesões o imunofenótipo foi
negativo em áreas lobulares e positivo em áreas ductais.
Conclusão: A caracterização imunofenotípica com E-caderina e β-catenina, combinada com a análise citológica
e arquitetural, pode destacar diferentes imunofenótipos e auxiliar na classificação dos CISM.Background
In situ breast carcinomas are classified, according to
their morphology, as ductal carcinoma in situ (DCIS) or
lobular neoplasia (LN), which includes lobular carcin-
oma in situ (LCIS) and atypical lobular hyperplasia
(ALH). According to the 2012 WHO classification of tu-
mors of the breast, classic LCIS is diagnosed when more
than half of the acini of a lobular unit are distended and
distorted by a dyshesive proliferation of cells with small,
uniform nuclei. Lesser involvement by the characteristic
cells is diagnosed as ALH. Lesions that show marked nu-
clear pleomorphism, with or without apocrine features
and comedonecrosis are referred as pleomorphic LCIS
(PLCIS) [1].
In some cases, the diagnostic criteria based on the
morphology of LN is not clear, leading to mistaken diag-
nosis of intraductal proliferative lesions. The main differ-
ential diagnoses of lobular neoplasia are: LN with solid
low-grade DCIS, PLCIS and high-grade DCIS. Some in
situ carcinomas present unusual cytological and / or
architectural features, making it difficult to determine
whether the proliferation is lobular or ductal. This group
has been called carcinomas in situ with a mixed or inde-
terminate pattern (CISM) [2,3].
The differential diagnosis of the CISM carries some im-
portant implications. Patients with LN are usually clinic-
ally monitored and can be offered tamoxifen as a
prophylactic therapy to prevent the development of inva-
sive carcinoma [4,5]. On other hand, patients with DCIS
should be treated by surgical removal of the lesion, with
clear margins followed by radiotherapy, or mastectomy
[6]. When diagnosed by core biopsy, DCIS should be
treated with complete excision of the lesion. However, the
clinical significance and therapeutic implications of finding
LN in core biopsy specimens are still controversial [7,8].
The diagnosis of CISM is extremely rare and studies
assessing the differential diagnosis of these lesions are
scarce and include only a few patients. The largest series
reported between 12 and 28 cases [9,10]. Previous studies
by our group identified 0.08% of CISM among breast bi-
opsies performed in our general hospital [11]. Although
rare, when analyzed under light microscope, the CISMlesions are difficult to diagnose and there is lack of
epidemiological data linked to their biological behavior.
A great progress in the diagnosis of these lesions came
with the observation that almost all cases of LN and in-
vasive lobular carcinoma (ILC) lose the immunohisto-
chemistry (IHC) signal for E-cadherin and β-catenin
expression in the cytoplasm membrane, whereas the ex-
pression of these proteins is maintained in both in situ
and invasive ductal carcinomas [3,12,13]. The cadherins
comprise a large number of adhesion molecules local-
ized in the intercellular junctions, keeping cells connec-
ted through homophilic protein-protein interactions.
The observation that cadherins play an important role in
the establishment of the epithelial phenotype, cell migra-
tion, cell differentiation, and tumor dissemination has
stimulated great interest in this family of adhesion mole-
cules. Among them is the Human Epithelial Cadherin
(E-cadherin), a calcium-dependent transmembrane glyco-
protein directly involved in the process of cell adhesion
[14]. The α, β, p, and γ catenins play important roles in
intercellular signal transduction. The β-catenin, specific-
ally, binds to the cytoplasmatic portion of the E-cadherin
and to the structure of actin microfilaments of the cyto-
skeleton as well, being involved in cell adhesion [15,16].
The E-cadherin gene mutation is the major mechanism
responsible for its inactivation in cancer cells and is asso-
ciated with other carcinomas, such as hepatocellular car-
cinoma, diffuse-type gastric cancer, thyroid and colorectal
cancer [16,17]. Another route resulting in inactivation of
E-cadherin is attributed to dysfunctional promoter activity
or DNA methylation at the promoter region [17,18].
The aim of this study was to evaluate the expression
of E-cadherin and β-catenin for the immunopheno-
typical characterization of carcinomas in situ with mixed
pattern, and identify potential morphological patterns
that could assist in the diagnosis of the different types of
CISM lesions.
Methods
This is a retrospective, descriptive study that analyzed 25
cases of breast biopsies (wide local excision or mastec-
tomy) performed between 1999 and 2011. The study
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able at the Laboratory of Breast Pathology at the School
of Medicine at the Federal University of Minas Gerais
(UFMG), Brazil. We selected one or more slides stained
with hematoxylin and eosin (HE) and which were repre-
sentative of each diagnosis of in situ carcinoma with
mixed pattern. The slides were analyzed simultaneously
by two of the authors (HG and DSG) using a dual-view
microscope and classified according to the standard
morphological patterns and immunohistochemical ex-
pression of E-cadherin and β-catenin. Cases without
available slides and / or paraffin blocks were excluded
from the study. The study was approved by the UFMG
research ethics committee.
Morphological evaluation
In situ lesions matching the LN morphological pattern
were characterized according to the proliferation of
generally small, dyshesive cells, with uniform round
nuclei and clear cytoplasm. The acini are partially or
completely expanded, but the lobular architecture is
maintained [1]. Lesions classified as DCIS presented
proliferation of monomorphic cells with regular distribu-
tion, and hyperchromatic nuclei forming regular second-
ary, rounded, and uniform lumens. The in situ lesions
characterized as mixed pattern presented cytological or
architectural features common to the ductal and lobular
lesions and were classified into three main patterns
according to criteria previously described by Jacobs et al.
[3]: Group 1 – those presenting architectural andA
C
Figure 1 Case # 1: Lobular neoplasia (arrows) and ductal carcinoma in
breast field (hematoxylin and eosin; A – 100×). Cells of ductal carcinom
negative for E-cadherin (B, 100× and C, 400×).cytological findings of LN but with areas of comedo-type
necrosis; Group 2 – those with CISM lesions character-
ized by small and uniform cells, either growing in a solid
pattern with focal microacinar-like structures but with
cellular dyshesion, or growing in a mosaic pattern with
occasional intracytoplasmic vacuoles; Group 3 – those
with marked cellular pleomorphism and nuclear atypia,
however, the LN discohesive pattern remains.
Immunohistochemical evaluation
Sequential 5 μm thick histological sections were obtained
from the paraffin blocks from the breast specimens and
mounted on silanized slides. Sections were deparaffinized
in two consecutive baths of xylene, for 20 minutes each,
and rehydrated in ethanol series with decreasing concen-
trations and finally in distilled water. For antigen retrieval,
a buffer solution of 10 mM citrate pH 6.0 was used in an
electrical pressure-cooker. Immunohistochemistry was
performed automatically using Ventana Benchmark XT
equipment (Ventana Medical Systems Inc., Tucson, AZ,
USA). E-cadherin (clone 36) and β-catenin (clone 18) anti-
bodies were used, at titers of 1:600 and 1:800, respect-
ively. Antibodies were purchased from BD Transduction
(cat# C19220), San Jose, CA, USA.
The non-biotinylated polymer system (Novolink®,
Leica Microsystens) technique was used for reaction
amplification. A diaminobenzidine (DAB) solution was
used as chromogen and the slides were counter-stained
using Harris hematoxylin. External positive and negative
controls were used. Normal ducts and lobules, adjacentB
D
situ of cribriform type (arrowheads) are present in the same
a stain positive (B,100× and D, 400×) and cells of lobular neoplasia are
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in the epithelium, were used as internal controls.
Staining for E-cadherin and β-catenin was considered
positive when the staining intensity around the entire
circumference of the membrane was similar to that seen
in the normal luminal epithelial cells. No staining was
considered as negative (Figure 1).
Results
Twenty-five cases of CISM were identified from the
Breast Pathology Laboratory during the study period.
The average patient age was 52.7 (± 11.5) years. Nine-
teen cases (76%) presented morphological pattern show-
ing cytology and / or architectural mixed pattern (ductal
and lobular), two cases (8%) showed lobular architec-
tural pattern with nuclear pleomorphism, two cases (8%)
showed mixed cytology and nuclear pleomorphism, andTable 1 Morphology and immunophenotype of 25 breast car
biopsies
Morphological pattern
of in situ lesion
Morphology of in situ lesion w
Case # Lobular Ductal Mixed Nuclear
pleomorphism
Comedonecros
1 Yes Yes Yes No No
2 No No Yes No No
3 No No Yes No No
4 No No Yes No No
5 No No Yes Yes No
6 No No Yes No No
7 Yes No Yes No No
8 No No Yes No No
9 No No Yes Yes Yes
10 No No Yes No No
11 No Yes Yes No No
12 No No Yes No No
13 No No Yes Yes Yes
14 Yes Yes Yes No No
15 No Yes Yes No No
16 No No Yes Yes No
17 Yes No No Yes No
18 Yes Yes Yes No No
19 No Yes Yes No No
20 No No Yes No No
21 No No Yes No No
22 Yes Yes Yes No No
23 No No Yes No No
24 No No Yes Yes No
25 No Yes Yes No No
NA Not applied.two cases (8%) showed comedonecrosis and nuclear
pleomorphism (Table 1).
Immunohistochemistry for E-cadherin was performed
in all 25 cases. Eleven cases (44%) were positive for E-
cadherin (Figure 2). Thirteen cases (52%) showed mixed
immunophenotype with positive E-cadherin staining the
ductal cells and negative in the lobular areas. In one
case, the cells were completely negative for E-cadherin.
In all cases in which both markers were analyzed (20
cases) the immunohistochemical results agreed with
both E-cadherin and β-catenin. Immunohistochemistry
for β-catenin was not performed in five cases due to
sample processing artifacts and insufficient material for
the preparation of new slides.
Nineteen cases were composed by small, uniform cells
varying from low to intermediate nuclear grade, growing in
solid pattern, with some microacinar-like structures admi-cinomas in situ with mixed pattern analyzed from breast
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Figure 2 Case # 8: Carcinoma in situ with mixed pattern (CISM) showing dual cell population (Group 2) stained for hematoxylin and
eosin (A – 100×, B – 400×). A stronger positive membrane staining for E-cadherin (C – 400×) and β-catenin (D – 400×) can be appreciated in
the outer layer of cells of ductal pattern. A weaker staining is seen in cells of lobular pattern present in the center of the units.
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mosaic pattern. Of these, 11 (57.9%) presented positive im-
munohistochemistry for E-cadherin and β-catenin. In these
cases, solid architecture with low-grade cytology was the
most common morphological pattern. Eight of these cases
(42.1%) presented the mixed immunophenotype and in four
of them, the mixed pattern resulted from a “collision” of the
lesions showing areas positive and areas negative for both
markers in the same duct-lobular unit (Figure 3).
Two cases presented the lobular architectural pattern
with nuclear pleomorphism and two cases presented
mixed cytology and nuclear pleomorphism. The last two
cases were considered as mixed immunophenotype. Of
the two cases that presented comedonecrosis and nuclear
pleomorphism, one was completely negative for both
markers (Figure 4) and the other presented cells positive
and cells negative for both markers (Table 2).
Discussion
In this study, we sought to evaluate the expression of E-
cadherin and β-catenin for the immunophenotypical
characterization of CISM. We also searched for potential
morphological patterns that could help in the diagnosis
of different types of CISM lesions. We adopted the mor-
phological classification described by Jacobs et al. that
defines CISM as “carcinomas with indeterminate fea-
tures”[3]. According to this classification CISM lesions
are divided in three main groups, namely: (I) presence of
necrosis, (II) cytology and / or mixed architecture, and
(III) nuclear polymorphism. This classification is highlyreproducible and addresses the main morphological
groups described in our study.
A total of 25 CISM cases were evaluated in this study.
The most common morphological pattern of lesions
identified belonged to group (II) with 19 out of 25 cases
(76%), followed by group (III) (2/25 cases - 8%), and
overlapping patterns between groups (I) and (II) (2/25
cases - 8%) and groups (II) and (III) (2/25 cases - 8%).
Our findings are in agreement with those reported by
Jacobs et al. who observed, in 28 cases of CISM, 60% of
the lesions in group (II) (17/28 cases), 21% in group (I)
(5/28 cases) , and 18% in group (III) (5/28 cases).
However, it is noteworthy that the terminology and mor-
phologic criteria used for the diagnosis of CISM are hetero-
geneous. Fisher et al. termed it as “ductolobular carcinoma
in situ” lesions with monomorphic cells with foci of necro-
sis or cribriform pattern [4]. Acs et al. described 14 cases of
CISM referring to the lesions as “with ductal carcinoma in
situ and lobular features” and adopted, as a diagnostic cri-
teria, LN in situ lesions with cytological and architectural
patterns, with central areas of comedonecrosis or lobules,
or large duct units populated by non-cohesive cells with
marked nuclear pleomorphism [19]. Maluf et al. analyzed
12 cases of “solid low grade carcinoma in situ of the breast”
and included “low-grade solid DCIS, LCIS and DCIS and
LCIS associated with invasive carcinomas of any type.
Cases showing only unequivocal areas of LCIS or DCIS of
nonsolid type were excluded” [20].
Even among experts in the pathology of breast tumors,
the descriptions of these lesions are divergent. Page and
Figure 3 Case # 16: Carcinoma in situ with mixed pattern (CISM) showing dual cell population stained for hematoxylin and eosin,
involving a papilloma and adjacent ducts. Areas of pleomorphic lobular pattern show discohesive atypical cells (arrows). Areas of “ductal”
pattern show proliferation of cohesive cells with hyperchromatic nuclei forming secondary, rounded, and uniform lumens (arrowheads), (A, 200×
and B, 400×). A mixed pattern resulted from a “collision” of both cell types in the same duct-lobular unit. “Ductal” cells are positive for E-cadherin
(arrowheads) and lobular cells are negative (C and E– 200×, D and F – 400×).
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made to classify the lesions as LN or DCIS [21]. How-
ever, on rare occasions this might not be possible and
the diagnosis of “in situ carcinoma of ductal or lobular
type” needs to be made. These authors recommend that
if more than one focus of necrosis is found, the lesion
should not be classified as LN. Rosen describes two
main types of CISM: “concurrent intraductal and lobular
carcinoma in situ” for lesions that present a cytology of
lobular pattern and distended ducts and central necrosis
or calcifications, and “coexistent intraductal and lobular
carcinoma in situ in a single duct-lobular unit.” The au-
thor uses this description to refer to the more unusual
intraductal lesions characterized by the presence of two
distinct architectural and cytological patterns [22].
Recently, in situ lesions with lobular cytological features
of classic LCIS but with marked nuclear pleomorphism,
comedonecrosis, and with or without apocrine cytology
have been described as pleomorphic LCIS [1]. Somereports suggest that these variants are more aggressive than
classic LN and a surgical treatment similar to that applied
to DCIS is recommended. However , there are no prospect-
ive epidemiological studies showing that these variants have
different clinical significance and appropriate management
of pleomorphic LCIS is currently uncertain [1].
In our series, we observed a frequent association
between immunophenotype and morphology (cytoar-
chitectural features). Lesions in group (II), with solid
architecture and low-grade cytology, were more often as-
sociated with expression of E-cadherin. Our data differ
from those reported by Acs et al., in which no expression
of E-cadherin was observed in the 14 CISM cases ana-
lyzed. The most frequent morphological pattern observed
in that study was presence of lobular cytology with
comedonecrosis (n = 9 ) [19]. Maluf et al. analyzed 12
CISM cases and detected E-cadherin expression in five,
while another five cases showed no expression of the pro-
tein and two presented a mixed population of cells in this
BC D
A
Figure 4 Case # 13: Pleomorphic lobular carcinoma in situ showing discohesive atypical cells, with nuclear pleomorphism and
comedonecrosis. Hematoxylin and eosin (A – 100×). Lobular cells are negative for E-cadherin (B – 100×; D – 400×) and for β-catenin (C – 100×).
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specific morphological pattern over others [20]. Similarly
to the study by Jacobs et al., lesions in group (II) were
the most frequent lesion associated with expression of
E-cadherin in our study, however we observed them at a
higher frequency. A dual cell population in the same ter-
minal duct-lobular unit was observed in four cases. This is
likely due to the coexistence of LN and DCIS in the same
terminal duct-lobular unit.
Since first reported, the immunohistochemical reac-
tion of E-cadherin has been proposed as an aiding tool
in the differential diagnosis between ductal and lobular
lesions, either invasive or in situ. However, it should be
noted that up to 15% of lobular lesions may exhibit aber-
rant expression of E-cadherin and thus, the lack of
E-cadherin expression should not be used as the sole cri-
terion for LN diagnosis [12]. Choi et al. observed
variability in the immunohistochemical staining ofTable 2 Category morphology and immunophenotype for
E-cadherin of carcinoma in situ with mixed pattern
Morphology Cases E-cadherin
Positive Negative Mixed
Group 1 0 0 0 0
Group 2 19 11 0 8
Group 3 2 0 0 2
Group 2 and 3 2 0 0 2
Group 1 and 3 2 0 1 0
Total 25 11 1 13E-cadherin, and detected abnormal staining patterns,
both in ductal and lobular lesions, making the differen-
tial diagnosis between in situ lobular and invasive lesions
very difficult through immunohistochemistry [10]. An
alternative to reduce this interference and improve diag-
nosis is the combined use of immunohistochemical
markers of the catenin pathway. Using IHC and molecu-
lar biology techniques Da Silva et al. analyzed three
cases presenting morphological characteristics and geno-
typing that agreed with invasive lobular carcinoma, with
nonetheless aberrant expression of E-cadherin. Of these
three cases, two did not express β-catenin, indicating
that the formation of the cadherin-catenin complex,
which is required for the normal function of the cell and
maintenance of tissue architecture, including cell adhe-
sion, failed [12,23]. In our study, we observed that
expression of E-cadherin agreed with expression of
β-catenin in all cases here observed.
Other explanations for the abnormal expression of
E-cadherin found in other studies may be related to
technical difficulties and pitfalls that may occur during
the different stages in the immunohistochemical reac-
tion. In our study, we had some difficulties in the
pre-analytical reaction such as material loss and weak
staining in some cases. This may reflect the fact that
we used specimens coming from the routine diagnosis la-
boratory of a general hospital; and other cases were sent
to us for a second opinion. In many cases, there was no
control of the pre-analytical phase or standardization of
time of formalin fixation and unbuffered formalin was
used. Goldstein et al. showed that the reactivity level varies
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sections in the pre-analytical process [2]. Different
clones of antibodies against E-cadherin and different an-
tigens may also have an effect on the quality of the im-
munohistochemical staining. A comparison between two
types of antibodies revealed discrepancy in the staining
of lobular lesions in 6.4% of the cases [7]. Finally, there
is a lack of consensus regarding the interpretation
of the positivity of immunohistochemical staining of
E-cadherin. The established cutoff of a positive signal
varies between basal membrane expression and presence
of any positivity to 20% of expressing cells [12,23]. Semi-
quantitative evaluations of the intensity of staining and
association of different criteria forming scores of staining
intensity have also been proposed [19].
Other immunohistochemical markers have been sug-
gested to aid in the diagnosis of CISM. The p120 catenin
is an intracellular protein that promotes the binding be-
tween the complex of catenins and cell cytoskeleton.
When E-cadherin expression is absent, p120 catenin is
dispersed in the cytoplasm, which explains its expres-
sion in the cytoplasm in LN, and in the membrane in
DCIS [23,24].
Conclusions
The immunophenotypic characterization of carcinomas
in situ using E-cadherin and β-catenin, combined with
the analysis of cytological and architectural patterns, is a
useful tool for the morphological and immunophe-
notypical classification of CISM. However, a negative
staining for these markers should not be used as the sole
criterion of lobular phenotype because aberrant expres-
sion in lobular neoplasia and loss of expression in ductal
cancers can both occur.
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